Patents by Inventor Mark George Saulnier

Mark George Saulnier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS
    Publication number: 20240101539
    Abstract: Extracellular protein degraders and compositions are provided that have a potent asialoglycoprotein receptor (ASGPR) Binding Ligand bound to an Extracellular Protein Targeting Ligand for the selective degradation of the Target Extracellular Protein, for example immunoglobulin in vivo to treat disorders mediated by the extracellular protein.
    Type: Application
    Filed: July 11, 2023
    Publication date: March 28, 2024
    Applicant: Avilar Therapeutics, Inc.
    Inventors: Jason Allan Wiles, Srinivasa Karra, Mark George Saulnier, Jesse Jingyang Chen, Kevin Tyler Sprott, Soumya Ray
  • ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS
    Publication number: 20240072809
    Abstract: Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described.
    Type: Application
    Filed: July 11, 2023
    Publication date: February 29, 2024
    Applicant: Avilar Therapeutics, Inc.
    Inventors: Mark George Saulnier, Jesse Jingyang Chen, Srinivasa Karra, Kevin Tyler Sprott, Jason Allan Wiles, Soumya Ray
  • ASGPR-binding compounds for the degradation of extracellular proteins
    Patent number: 11819551
    Abstract: Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described.
    Type: Grant
    Filed: July 29, 2022
    Date of Patent: November 21, 2023
    Assignee: Avilar Therapeutics, Inc.
    Inventors: Mark George Saulnier, Jesse Jingyang Chen, Srinivasa Karra, Kevin Tyler Sprott, Jason Allan Wiles, Soumya Ray
  • ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS
    Publication number: 20230097256
    Abstract: Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described.
    Type: Application
    Filed: July 29, 2022
    Publication date: March 30, 2023
    Applicant: Avilar Therapeutics, Inc.
    Inventors: Mark George Saulnier, Jesse Jingyang Chen, Srinivasa Karra, Kevin Tyler Sprott, Jason Allan Wiles, Soumya Ray
  • Compounds useful as immunomodulators
    Patent number: 10745382
    Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: August 18, 2020
    Assignee: bristol-myers squibb company
    Inventors: Kap-Sun Yeung, Timothy P. Connolly, David B. Frennesson, Katharine A. Grant-Young, Piyasena Hewawasam, David R. Langley, Zhaoxing Meng, Eric Mull, Kyle E. Parcella, Mark George Saulnier, Li-Qiang Sun, Alan Xiangdong Wang, Ningning Xu, Juliang Zhu, Paul Michael Scola
  • COMPOUNDS USEFUL AS IMMUNOMODULATORS
    Publication number: 20170107202
    Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: October 11, 2016
    Publication date: April 20, 2017
    Inventors: KAP-SUN YEUNG, Timothy P. Connolly, David B. Frennesson, Katharine A. Grant-Young, Piyasena Hewawasam, David R. Langley, Zhaoxing Meng, Eric Mull, Kyle E. Parcella, Mark George Saulnier, Li-Qiang Sun, Alan Xiangdong Wang, Ningning Xu, Juliang Zhu, Paul Michael Scola
  • Sulfonamide compounds useful as CYP17 inhibitors
    Patent number: 8916553
    Abstract: Disclosed are sulfonamide compounds of Formula (I): or stereoisomers, N-oxides, prodrugs, or pharmaceutically acceptable salts thereof, wherein ring A, R1, R2, R3, R4 and R5 are defined herein. Also disclosed are methods of using such compounds in the treatment of conditions related to CYP17 enzyme, such as cancer, and pharmaceutical compositions comprising such compounds.
    Type: Grant
    Filed: July 25, 2011
    Date of Patent: December 23, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Joel Francis Austin, Lisa S. Sharma, James Aaron Balog, Audris Huang, Upender Velaparthi, Chetan Padmakar Darne, Mark George Saulnier
  • SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS
    Publication number: 20140148453
    Abstract: Disclosed are sulfonamide compounds of Formula (I): or stereoisomers, N-oxides, prodrugs, or pharmaceutically acceptable salts thereof, wherein ring A, R1, R2, R3, R4 and R5 are defined herein. Also disclosed are methods of using such compounds in the treatment of conditions related to CYP17 enzyme, such as cancer, and pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: July 25, 2011
    Publication date: May 29, 2014
    Inventors: Joel Francis Austin, Lisa S. Sharma, James Aaron Balog, Audris Huang, Upender Velaparthi, Chetan Padmakar Darne, Mark George Saulnier